Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Body Count Linked to GSK Vaccine Trial Rises
- Fourteen children have now died during a pneumonia vaccine trial run by GlaxoSmithKline in Argentina, according to the U.K.'s Daily Mail. Argentine authorities are investigating. GSK says the deaths are not linked to the tests. This issue first emerged for GSK in July, when TradingMarkets.com reported that...
- Blog posts 2008-08-18
Additional Resources
- GSK forms JV to expand in Chinese vaccine market
- The joint venture strengthens GlaxoSmithKline's GSK position in two growth areas, China and vaccines, and is in keeping with the pharma's recent strategy. GSK has signed a similar deal with China-based Shenzhen Neptunus Interlong Bio-Technique to develop and manufacture flu vaccines. By making these deals Jean Stephenne, president of GSK...
- News items 2009-10-07
- GSK Seeks to Increase Emerging Markets Presence with New Vaccine JV
- ChinaBio Today submits: GlaxoSmithKline (NYSE: GSK) has formed a vaccine JV with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT), an established China vaccine company. The JV will produce flu vaccines for the China market. It will seek to increase GSK’s presence in emerging markets, which is one of the...
- External links 2009-06-10
- GSK steps along desired path of evolution
- Andrew Witty, chief executive of GlaxoSmithKline, said on Wednesday that the group's traditional core market of prescription medicines in developed countries may fall to just a quarter of total sales. He also said that further diversification would focus more on revenue growth than profit margins. Unveiling third-quarter results, Mr Witty,...
- News items 2009-10-28
- GSK deal draws smokers' vaccine closer
- Smokers may soon be able to break their habit with an injectable vaccine that prevents nicotine in tobacco entering the brain, where it creates a highly addictive sensation of pleasure. The NicVAX vaccine moved closer to the market on Monday after a deal between GlaxoSmithKline and the US biotech company...
- News items 2009-11-16
- Vaccine for smokers draws closer as GSK agrees US biotech deal
- Smokers may soon be able to break their habit with an injectable vaccine that prevents nicotine in tobacco entering the brain, where it creates a highly addictive sensation of pleasure. The NicVAX vaccine moved closer to the market yesterday after a deal between GlaxoSmithKline and the US biotech company Nabi...
- News items 2009-11-17
- Glaxo and AFFiRiS Sign Alzheimer?s Disease Vaccine Deal
- Eben Tessari submits: GlaxoSmithKline Biologicals GSK and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programs, aimed at treating Alzheimer’s by targeting beta-amyloid. As part of the agreement, GSK is acquiring exclusive rights to develop and commercialize two Alzheimer’s...
- External links 2008-10-30
- Sinovac Launches New Version of Flu Vaccine
- ChinaBio Today submits: Sinovac Biotech Ltd. SVA announced the launch of the 2008-2009 version of its seasonal flu vaccine, Anflu. Anflu is the only split influenza vaccine produced without preservatives in China. Sinovac said it would market the vaccine to adults. Last year, Sinovac signed a co-promotion...
- External links 2008-09-11
- GlaxoSmithKline Forms Vaccine JV for the China Market
- ChinaBio Today submits: GlaxoSmithKline (NYSE: GSK) has formed a JV with Jiangsu Walvax Biotech Company to develop and manufacture pediatric vaccines for the China market. Initially, the JV will be funded with $65.6 million of capital, of which $32 million (65%) will come from GSK. GSK has also agreed...
- External links 2009-10-07
- FFF Enterprises and GlaxoSmithKline Sign Agreement on Flu Vaccine Distribution
- TEMECULA, Calif. -- FFF Enterprises Inc., a national distributor of flu vaccine, based in Temecula, has been selected by GlaxoSmithKline GSK to distribute additional doses of FluarixTM influenza vaccine for the coming 2006-2007 flu season. Already contracted to distribute vaccine for GSK and the other two manufacturers of the three...
- Research articles 2006-06-26
- GLAXOSMITHKLINE (GSK).
- GlaxoSmithKline GSK, which announces its first-quarter results on 28 April, has had something of a mixed start to the year. While the drug giant's new cervical cancer vaccine, Cervarix, has been hailed as a potential blockbuster by analysts, manufa GlaxoSmithKline GSK, which announces its first-quarter results...
- Research articles 2005-04-22
- GLAXOSMITHKLINE (GSK).
- Alongside its peers, AstraZeneca and Shire, GlaxoSmithKline GSK posted a robust set of first-quarter figures, which pushed its shares up 4 per cent to 1,548p. During the period, the pharma giant filed its cervical cancer vaccine, Cervarix, for appr Alongside its peers, AstraZeneca and Shire, GlaxoSmithKline...
- Research articles 2006-05-05
- GLAXOSMITHKLINE (GSK).
- GlaxoSmithKline's GSK cervical cancer vaccine, Cervarix, may have the edge over US rival Merck's product Gardasil, according to trial results presented this week in America. GlaxoSmithKline's GSK cervical cancer vaccine, Cervarix, may have the edge over US rival Merck's product Gardasil, according...
- Research articles 2006-03-03
- GLAXOSMITHKLINE (GSK).
- Encouraging results from trials of GlaxoSmithKline's GSK pandemic 'flu vaccine formed the centrepiece of the group's half-year results. This new product for the virulent H5N1 strain produced a strong immune response in 80 per cent of patients. Furt Encouraging results from trials of GlaxoSmithKline's GSK ...
- Research articles 2006-08-04
- GlaxoSmithKline and Merck & Co., Inc. Enter Cross-License and Settlement Agreement for HPV Vaccine Patents
- WHITEHOUSE STATION, N.J. & PHILADELPHIA -- Merck & Co., Inc. (NYSE: MRK) and GlaxoSmithKline (NYSE: GSK) have entered into a cross-license and settlement agreement for certain patent rights related to human papillomavirus ("HPV") vaccine. GSK will receive an upfront payment and royalties from Merck based upon sales of a HPV...
- Research articles 2005-02-02
- GLAXOSMITHKLINE TO SET UP VACCINE R&D CENTER IN TAIWAN.
- TAIPEI, Sept 4 Asia Pulse - The world's second largest pharmaceutical company, GlaxoSmithKline GSK, is planning to set up a vaccine research and development center in Taiwan, sources from the Executive Yuan said Wednesday. TAIPEI, Sept 4 Asia Pulse - The world's second largest...
- Research articles 2003-09-04
- AVANT Announces Latest GSK Report on Sales of Rotarix® Evidences Disagreement on Royalty Rate in Patent Countries
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that GlaxoSmithKline GSK paid royalties on GSK's sales of RotarixR rotavirus vaccine in Australia and certain European countries at the lower of two royalty rates under their 1997 license agreement. GSK's decision to pay the lower royalty rate (which is...
- Research articles 2006-09-20
- FFF Enterprises Signs Flu Vaccine Agreement with GlaxoSmithKline; Biopharmaceutical Supply Channel Innovator Receives U.S. Distribution Deal
- TEMECULA, Calif. -- FFF Enterprises Inc., a healthcare corporation based in Temecula, today announced that GlaxoSmithKline GSK has awarded FFF a contract for the U.S. distribution of GSK's influenza vaccine, FluarixTM, for the 2006-2007 season. FFF helped launch Fluarix in the United States as a preferred distributor during the current...
- Research articles 2005-12-06
- GlaxoSmithKline Continues Power Play in Hot Global Vaccine Market with $1.4 Billion Buyout Offer for Canada's ID Biomedical
- HOUSTON -- Researched by Industrialinfo.com (Industrial Information Resources, Incorporated; Houston, Texas). With the flu season fast approaching amidst the not-so-distant memories of last year's vaccine supply fiasco, British drugmaker GlaxoSmithKline plc (http://moneycentral.msn.com/investor/research/profile.asp?Symbol=GSK) (NYSE:GSK) has made a strategic move for growth in the sector.
- Research articles 2005-09-23
- FFF Enterprises Signs Flu Vaccine Distribution Agreement with GlaxoSmithKline; Accord Will Ensure a Secure and Reliable Distribution Channel for Fluarix Upon FDA Approval
- TEMECULA, Calif. -- FFF Enterprises Inc., a healthcare corporation based in Temecula, today announced it has signed an agreement with GlaxoSmithKline for the distribution of its candidate influenza vaccine, FluarixTM. GlaxoSmithKline GSK recently submitted a Biological License Application to the U.S. Food and Drug Administration FDA, to market Fluarix in...
- Research articles 2005-06-20
- << Previous
- page 1 of 1
- Next >>
Presented by American Express